Bear market hits Europe’s innovator drug venture financing, losing pace with US
US-based biotech venture financing for innovator drugs reached a total of $72bn from 2017 to 2022, while Europe raised only…
By
Business & Regulation
Latest in
Business & Regulation
Bursting biotech bubble: venture capitals rethink private companies in Q1 2022
Venture capital firms seem to be more selective in their biotech investments following increased venture financing last year.
By
Covid-19 patent lawsuits: Will vaccine producers have to pay the bill?
Moderna’s positioning as US contractor for Covid-19 vaccines in a patent lawsuit marks a new development in the infringement disputes.
By
Precise magnitude of hospital markups revealed in the US
A recent study has shed light on the size of markups imposed by hospitals for parenteral cancer drugs in the…
By
Holistic thinking is prescribed for investors on World Health Day 2022
World Health Day 2022 offers investors the opportunity to think beyond the laboratories and consider the impact their healthcare activities…
By
Will Russia’s invasion affect biopharmaceutical licensing agreements?
Western sanctions may make companies cautious about entering any strategic alliances with or receiving any capital from Russia.
By
Sanctions hit Russian investors with limited impact on foreign innovator drugs
Overall venture capital financing from US investors for foreign innovator drugs is almost 500 times that from Russian investors.
By
Fall from grace? What 2022 may have in stock for biopharmaceutical SPACs
It remains to be seen whether the special purpose acquisition company (SPAC) trend will continue as markets rebuild post-pandemic.
By